Go back

Stryker Stock Is Undervalued - SYK Stock Analysis

from Trading Fundamentals

7m 46s

Stryker Stock Is Undervalued - SYK Stock Analysis

Striker, a U.S.-based medical device company with global operations, has demonstrated strong financial resilience despite a 20% stock decline over the past year. Its revenue has grown from $11.3 billion in 2016 to $25.1 billion in 2025, with an annualized growth rate of 9.3%, and free cash flow has expanded at a faster 12.7% rate. The company’s free cash flow margin has improved from 13% to 18%, aligning with industry standards. While 76% of revenue comes from the U.S., both its medical technology (62%) and orthopedics (38%) segments show consistent year-over-year revenue growth. Strategic acquisitions, peaking in 2025 at $4.96 billion, are a key growth driver. Striker trades at a trailing PEG ratio of 1.2 and a price-to-cash flow of 21—its lowest valuation in a decade—making it a compelling value opportunity. Despite a 1.2% dividend yield (near its 10-year high), the 34-year dividend growth streak and low payout ratio (28%) indicate financial strength. However, the company is shifting focus toward innovation and acquisitions, reducing dividend growth momentum. The stock is currently below its 5-year average price (19% discount), with technical indicators suggesting a bounce from support at $265. While competitive pressures in the medical device space remain a risk, Striker’s essential nature, stable revenue, and strong cash flow position it as a solid growth investment, not a dividend-focused play.

Transcription

1294 Words, 7591 Characters

English
Striker stock is fallen by nearly 20% over the past year, while their free cash flow year of a year has grown by 9.8%. In better still, Striker is trading at a trailing PEG ratio of 1.2, but has the market mispriced Striker stock where are their valid risks worth avoiding? Striker is a US-based medical device company that sells products globally. According to their annual report, they sell products in 61 countries, but the US makes up the vast majority of revenue coming in at 76%, while the 61 countries mentioned before only contribute 24% of revenue. For reference, this is a fairly low proportion of international sales. If we compare Striker to Boston Scientific, Abbott, or Becton Dickinson, as far as their business segments go, they divide their business into two main segments. The largest being med surge in neuro-technology at 62% of sales, which refers to surgical equipment and a long list of other medical products all lumped into one category. Their secondary business segment is orthopedics at 38% of revenue, which mostly sells joint replacement products for various segments of the body. The simplest advantage to Striker's business is that their products are essential if not important to a given patient's health and whatever application they're being utilized in. And essential businesses are some of the easiest businesses to buy with confidence, at least in my experience. We can see the essential nature of medical devices and strikers' results, as each business segment broken down into their smallest groups have grown in revenue each year since 2023, with the exception of spinal implants. And this growth pattern is the same for revenue broken down by region as well. What of this growth in revenue is the result of acquisitions, which is a regular part of Striker's capital management strategy, and look how easy Striker has made it for investors to find this information, with six years of data all on one 10K. We can see that 2025 was their largest year for acquisitions at $4.96 billion, which nearly ate up the entirety of their operating cash flow. While their smallest year for acquisitions recently wasn't 2021 at just $339 million. Personally, I see consistent acquisitions in the medical device industry as a great way to gain market share, and to be on the cutting edge of technology, assuming acquisitions are for good products or companies at fair valuations. I see one main risk investing in a business like Striker, which is that the medical device industry is highly competitive since its technology and innovation driven. And each company in this space has to continually develop new tools in order to outperform their competition. So it's not a simple business that can just passively generate cash flow like a railroad company could, for example. Other than the negative of steep competition, I see medical device companies like Striker as being safe investments in an essential industry. Striker's revenue has grown from $11.3 billion in 2016 to $25.1 billion as of 2025, which is an annualized growth rate of 9.3%, which is quite good, in my opinion, especially considering how stable their revenue is, but only one year of revenue decline in 2020, which was minuscule anyway and justifiable. Free cash flow per share is growing even faster than revenue at an annualized rate of 12.7% from 2016 to 2025, which is a solid growth rate, especially considering this a per share metric, and their deluding shareholders consistently, and an annualized rate of 0.23%, which is minor but still disappointing. As you may have expected since free cash flow is growing faster than revenue, Striker's free cash flow margin has improved over this period, growing from 13% to 18% as of the trailing 12 months, and Striker looks to be on par with the industry standard around an 18% free cash flow margin. Now we see the balance sheet, and Striker has a total liabilities level of $23.9 billion, and like so many companies, their liabilities have grown substantially, starting at just $10.9 billion in 2016, or an annualized growth rate of 9.9%, which slightly outpaces revenue growth over the same period. If we take their total liabilities and add back their cash and equivalence, we get a true liabilities level of $20.5 billion, and if we divide that by their trailing 12 months net income, they have a fairly low total liabilities to net income ratio of 5.5 times. In terms of valuation, I think this is where Striker seems most attractive, since its trading at a trailing price to cash flow of 21 times, which is the lowest valuation level you could have purchased Striker for over the past decade. Although if we use the trailing PE ratio currently at 31.8 compared to Striker's peer group, using the medical device ETF IHI at a PE ratio of 30.5 times, SYK looks to be slightly overvalued. Another way we could value Striker while counting for their fairly fast earnings growth rate is by using the PEG ratio, which indicates value to be had at a PEG ratio of 1.2. In terms of Striker's dividend metrics, the current yield is low at just 1.2%, but relatively high compared to its own 10-year history, as its trading in the upper end of this range. This graph of the dividend yield over a 10-year period is a feature I love about seeking alpha, and if you like it too, I'll link in the description that offers $30 off the premium membership, which I'd also be compensated for. In terms of dividend growth, the dividend has grown fairly quickly at a 10-year annualized rate of 8.8%, a 5-year rate of 6.9%, and an even slower, trailing 12-month rate of just 4.8%. So, dividend growth is trending down over time, and it looks like management is prioritizing fundamental growth through acquisitions over dividend growth, which I actually prefer for businesses that require perpetual innovation. They have an admirable dividend growth streak of 34 years, which was even increased during the great financial crisis, and this growth streak looks like it could continue based on the dividend payout ratio, with a trailing 12-month payout ratio of only 28% based on free cash flow, and the payout ratio is trending down over the decade. So, if you're looking for dividend stability, Striker looks solid, but it seems like they're moving away from being a dividend growth company, and the yield is low, so Striker is more of a growth investment than a dividend growth investment. Here we see a 5-year price chart for Striker stock, ticker SYK, and over this period, Striker has had a return of just 12.5%. The first measure of value we have here is the standard deviation channel, which determines an average price for a period marked by this center yellow line, which SYK is currently meaningfully below, with a current price of $307, while the average price is $381, or discount to the average of 19%. In terms of support and resistance, after a solid downtrend, price looks to have respected this support level round $265, which corresponds with the bottom of the standard deviation channel, and seems to be on a current uptrend. Lastly, the relative strength index, or RSI, graphed at the bottom of the chart, indicates that the bottom has already happened. With the RSI near the middle of the range at 48, but I think there's still more upside the downside potential. If you want to see a video of another medical device company that's trading and even better value than Striker, check out this video analyzing Boston's scientific stock. I'm not a financial advisor, and this is not on actual advice. This is for educational and entertainment purposes.

Podcast Summary

Key Points:

  1. Striker’s stock has declined by nearly 20% year-to-date, yet free cash flow has grown at 12.7% annually, outpacing revenue growth.
  2. The company operates globally with 61 countries, but 76% of revenue comes from the U.S., indicating limited international exposure.
  3. Striker’s business is split between medical devices (62% of sales) and orthopedics (38%), with both segments showing consistent revenue growth since 2023.
  4. Acquisitions have been a key capital strategy, with the largest in 2025 at $4.96 billion, though they have not disrupted core financial stability.
  5. Striker trades at a trailing PEG ratio of 1.2, suggesting fair value, and has a low trailing price-to-cash flow ratio of 21, the best in a decade.
  6. The company maintains a strong free cash flow margin (18%) and a low total liabilities-to-net-income ratio of 5.5, indicating solid balance sheet health.
  7. While the dividend yield is low at 1.2%, it’s near its 10-year high, and the 34-year dividend growth streak reflects strong historical stability.
  8. Striker is more of a growth investment than a dividend growth play, with management prioritizing innovation and acquisitions over dividend expansion.

Summary:

-based medical device company with global operations, has demonstrated strong financial resilience despite a 20% stock decline over the past year. 7% rate. The company’s free cash flow margin has improved from 13% to 18%, aligning with industry standards.

, both its medical technology (62%) and orthopedics (38%) segments show consistent year-over-year revenue growth. 96 billion, are a key growth driver. 2 and a price-to-cash flow of 21—its lowest valuation in a decade—making it a compelling value opportunity.

2% dividend yield (near its 10-year high), the 34-year dividend growth streak and low payout ratio (28%) indicate financial strength. However, the company is shifting focus toward innovation and acquisitions, reducing dividend growth momentum. The stock is currently below its 5-year average price (19% discount), with technical indicators suggesting a bounce from support at $265.

While competitive pressures in the medical device space remain a risk, Striker’s essential nature, stable revenue, and strong cash flow position it as a solid growth investment, not a dividend-focused play.

FAQs

Striker's revenue has grown from $11.3 billion in 2016 to $25.1 billion in 2025, representing an annualized growth rate of 9.3%.

Free cash flow per share is growing faster than revenue, with an annualized rate of 12.7% compared to 9.3% for revenue.

Striker's largest segment is med surge in neuro-technology, accounting for 62% of sales, and orthopedics, which makes up 38% of revenue.

Striker's free cash flow margin has improved from 13% to 18% over the period from 2016 to 2025, aligning with industry standards.

Striker trades at a trailing PEG ratio of 1.2, indicating reasonable value, though its trailing P/E of 31.8 is slightly above its peer group's average of 30.5.

The medical device industry is highly competitive and innovation-driven, requiring continuous product development to stay ahead of competitors.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.